Allakos Raises $10M in Funding

Allakos, a San Francisco Bay Area-based biotechnology company, raised an additional $10m in funding.

Backers included current investors Novo Ventures, Alta Partners, RiverVest Venture Partners and the Roche Venture Fund.

The company, which has raised a total of $42m in the Series A round, intends to use the funds to develop an additional therapeutic antibody.

Led by Christopher Bebbington, Chief Executive Officer, Nenad Tomasevic, Vice President, Research, and Alejandro Dorenbaum, MD, Chief Medical Officer, Allakos develops antibody-based therapeutics to treat allergic disease, inflammation and diseases characterized by excess production of inflammatory cells.
The company has generated a preclinical pipeline of novel antibodies targeting cell types implicated in allergic and inflammatory responses, which it intends to advance to clinical proof-of-concept.



Join the discussion